Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Top Cited Papers
Open Access
- 6 July 2006
- journal article
- practice guideline
- Published by Wiley in Clinical Endocrinology
- Vol. 65 (2) , 265-273
- https://doi.org/10.1111/j.1365-2265.2006.02562.x
Abstract
In June 2005, an ad hoc Expert Committee formed by the Pituitary Society convened during the 9th International Pituitary Congress in San Diego, California. Members of this committee consisted of invited international experts in the field, and included endocrinologists and neurosurgeons with recognized expertise in the management of prolactinomas. Discussions were held that included all interested participants to the Congress and resulted in formulation of these guidelines, which represent the current recommendations on the diagnosis and management of prolactinomas based upon comprehensive analysis and synthesis of all available data.Keywords
This publication has 54 references indexed in Scilit:
- Medication-Induced HyperprolactinemiaMayo Clinic Proceedings, 2005
- HyperprolactinemiaTreatments in Endocrinology, 2003
- Surgical Treatment of Prolactin-Secreting Pituitary Adenomas: Early Results and Long-Term OutcomeJournal of Clinical Endocrinology & Metabolism, 2002
- Growth hormone secretion elicited by GHRH, GHRP‐6 or GHRH plus GHRP‐6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapyClinical Endocrinology, 1998
- Cabergoline treatment for a large macroprolactinoma throughout pregnancyJournal of Obstetrics and Gynaecology, 1997
- Reproductive toxicity of cabergoline in mice, rats, and rabbitsReproductive Toxicology, 1996
- Pregnancy outcome after treatment with the ergot derivative, cabergolineReproductive Toxicology, 1996
- Letters to the EditorClinical Endocrinology, 1995
- Bromocriptine in pregnancy: Safety aspectsJournal of Molecular Medicine, 1987
- Pregnancy and the Hyperprolactinemic WomanNew England Journal of Medicine, 1985